USPTO serial 77715882
ALPHAGENIX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- NADELMAN, ANDREA KOYNER
- Law office
- TMO LAW OFFICE 110 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with ALPHAGENIX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Sioux Falls, SD
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biochemicals, namely, monoclonal antibodies for in vitro scientific or research use; Biochemicals, namely, polypeptides for in vitro research use; Biological Tissue, namely, a set of matched frozen and fixed human biological specimens derived from the division of one original specimen for use in scientific and medical research; Biological tissue, namely, blood, stem cells, umbilical cords and placentas for scientific and medical research use; Biomedical compounds, namely, peptide substrates used in analyzing and detecting certain toxins for clinical or medical laboratory use; Biomedical compounds, namely, peptide substrates used in analyzing and detecting certain toxins for laboratory or research use; Cells for scientific, laboratory or medical research; Chemical preparations for scientific purposes; Chemicals for use in biotechnological product development; Chemicals for use in the biochemical and chemical industry; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents to monitor toxicity of drugs; Diagnostic preparations for scientific or research use; Diagnostic preparations for scientific use; Diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; Kit comprising of regeneration solution, serum samples and sensor chips for scientific use.; Laboratory chemicals, namely, an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; Protein arrays and nucleotide arrays for scientific and medical research; Reagent kits comprising generic DNA circle, DNA primers, polymerase and buffers for use in biotechnology fields; Reagents and substrates, namely, chemical compounds for use in patterning at nano scale or near nano scale; Reagents for research purposes; Reagents for scientific or medical research use; Reagents for testing the sterility of pharmaceuticals and injectable solutions; Reagents for use in scientific apparatus for chemical or biological analysis; Stem cells for research or scientific purposes; Stem cells for research purposes; Test particles for biodetection systems, biological analogues and microscopic carrier beads with chemically attached DNA fragments for use in testing the operation of equipment used for analyzing air for the presence of harmful biological substances; Testing kits containing peptide substrates used in analyzing and detecting certain toxins for clinical or medical laboratory use; Testing kits containing peptide substrates used in analyzing and detecting certain toxins for laboratory or research use | ACTIVE | Jul 26, 2007 |
| 005 | Diagnostic agents, preparations and substances for medical purposes; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Diagnostic preparations for medical and veterinary use; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; for the treatment of inflammatory disorders; for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti- infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases and asthma | ACTIVE | — |
| 042 | (Based on Use in Commerce) Biological research; Chemical research; Chemical, biochemical, biological and bacteriological research and analysis; Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; Genetic mapping for scientific purposes; Genetic testing of laboratory animals for research purposes; Medical and scientific research services in the field of cancer treatment and diagnosis; Medical research; Pharmaceutical research and development; Pharmaceutical research services; Product research and development; Research and development of new products; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research and development of technology in the field of biomaterials; Research and development of vaccines and medicines; Scientific research and development; Scientific research in the field of genetics and genetic engineering(Based on Intent to Use) Bacteriological consultation and research; Bacteriological research; Bacteriological research and testing; Basic and clinical research in the field of respiratory science and medicine | ACTIVE | Jul 26, 2007 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 28, 2010 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jan 28, 2010 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jul 2, 2009 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 2, 2009 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 2, 2009 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 1, 2009 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 22, 2009 | MDSM | NOTICE OF DESIGN SEARCH CODE MAILED | — |
| Apr 21, 2009 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 20, 2009 | NWAP | NEW APPLICATION ENTERED | — |